题名

新型糖尿病用藥的突破－遠離心血管疾病

DOI

10.6666/ClinMed.2017.80.1.077

作者

莊茜；陳涵栩

关键词

糖尿病(diabetes mellitus) ； sodium glucose co-transporters 2 inhibitor(SGLT2 inhibitor) ； Glucagon-like peptide-1 analog(GLP-1 analog) ； 心血管風險(cardiovascular complications)

期刊名称

臨床醫學月刊

卷期/出版年月

80卷1期（2017 / 07 / 28）

页次

409 - 413

内容语文

繁體中文
中文摘要

糖尿病會引起許多併發症，包括小血管與大血管層面，過去研究顯示，降低血糖可以改善小血管併發症，但關於是否可以降低大血管併發症則未有定論。自2007年發現rosiglitazone反而會增加心肌梗塞的風險後，美國食品藥品監督管理局(FDA)便建議之後所有糖尿病的新藥上市前都必須要臨床試驗確立心血管方面的安全性，不過在這兩年間，陸續有幾篇研究在測試新藥安全性的同時，意外發現到包括empagliflozin(SGLT2 inhibitor)、liraglutide(GLP-1 analog)和semaglutide(GLP-1 analog)可以降低大血管併發症的風險，這結果引發學界許多討論。
主题分类 醫藥衛生 > 基礎醫學
醫藥衛生 > 社會醫學
参考文献
  1. Bloomgarden, ZT(2008).Glycemic control in diabetes: a tale of three studies.Diabetes Care,31,1913-1919.
  2. Davidson, MH(2011).Cardiovascular effects of glucagonlike peptide-1 agonists.Am J Cardiol,108,33b-41b.
  3. Green, JB,Bethel, MA,Armstrong, PW(2015).Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med,373,232-242.
  4. Hayward, RA,Reaven, PD,Wiitala, WL(2015).Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.N Engl J Med,372,2197-1206.
  5. Marso, SP,Bain, SC,Consoli, A(2016).Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med,375,1834-1844.
  6. Marso, SP,Daniels, GH,Brown-Frandsen, K(2016).Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med,375,311-322.
  7. Nissen, SE,Wolski, K(2007).Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med,356,2457-2471.
  8. Pfeffer, MA,Claggett, B,Diaz, R(2015).Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.N Engl J Med,373,2247-2257.
  9. Scirica, BM,Bhatt, DL,Braunwald, E(2013).Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.N Engl J Med,369,1317-1326.
  10. Skyler, JS,Bergenstal, R,Bonow, RO(2009).Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.J Am Coll Cardiol,53,298-304.
  11. Zinman, B,Wanner, C,Lachin, JM(2015).Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med,373,2117-2128.
  12. Zoungas, S,Chalmers, J,Neal, B(2014).Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.N Engl J Med,371,1392-1406.
print cancel